PURPOSE: Cytomegalovirus retinitis is the most common intraocular infection in patients
with acquired immunodeficiency syndrome (AIDS). With prolonged suppressive …

Objective: To determine the relative effectiveness of an oral formulation compared to a
standard intravenous regimen of ganciclovir in preventing the progression of …

Objectives: To study the temporal relationships between cytomegalovirus (CMV) viral load
and specific UL97 mutations in polymorphonuclear leukocytes (PMNL) and plasma samples …

The emergence of mutations conferring ganciclovir resistance was evaluated in an open-
label randomized clinical trial that compared oral valganciclovir with intravenous ganciclovir …

PURPOSE: To evaluate whether cytomegalovirus resistant to ganciclovir, detected in either
the blood or urine, correlates with adverse ocular outcomes. DESIGN: Prospective cohort …

Cytomegalovirus (CMV) retinitis is among the most common opportunistic infections in
patients with acquired immunodeficiency syndrome. In a prospective study of 210 patients …

To determine whether therapeutic intravitreal concentrations of ganciclovirare achieved after
intravenous administration, vitreous samples were obtained intraoperatively from 23 eyes of …

Purpose: To determine the incidence, pathophysiology, clinical outcome, and survival in
patients with clinically resistant retinitis. Methods: Cytomegalovirus (CIVIV) retinitis was …

ABSTRACT A patient with systemic cytomegalovirus (CMV), including chorioretinitis,
received localized and systemic ganciclovir, systemic cidofovir analog, and localized …

Background: The oral formulation of ganciclovir is approved at a dose of 3.0 g/day for
maintenance treatment of cytomegalovirus (CMV) retinitis following an initial induction …